LLY - Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weigh
LLY - Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.